Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate

A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 , by lattice parameters a, b and c of 7.800 ±0.001 , 13.406 ±0.002 and...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	TEDROW JASON S, LINTON CATHIE L, CHARUKAMNOETKANOK NAHATHAI, HENRY RODGER, MEI JIANZHANG, MELLICAN SEAN M
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page
container_issue
container_start_page
container_title
container_volume
creator	TEDROW JASON S LINTON CATHIE L CHARUKAMNOETKANOK NAHATHAI HENRY RODGER MEI JIANZHANG MELLICAN SEAN M
description	A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 , by lattice parameters a, b and c of 7.800 ±0.001 , 13.406 ±0.002 and 13.554 ±0.002 , respectively and α, and γ of 67.155±0.002, 79.724°±0.002° and 84.067±0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.
format	Patent
fullrecord	<record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US7745622B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US7745622B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US7745622B23</originalsourceid><addsrcrecordid>eNqNir0KwjAURrs4iPoOHSt4l7S1u0Vx6qJOIiXaWxpIbkJ-hjqIz-Qj-SRWFFyFDw4f54yjW2l757mUgjCuIMne40ppEkH5TiDpI1uk0JxMb4USjSDIoZdz0yENgOp5f0DCoJVBWz24xFvxOQp99yuDRR6fka5I6IJsNXGP02jUculw9uUkijfrfbkFNLpGZ_hlqH192BVFli8ZW7H0j-QFZrhH0A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate</title><source>esp@cenet</source><creator>TEDROW JASON S ; LINTON CATHIE L ; CHARUKAMNOETKANOK NAHATHAI ; HENRY RODGER ; MEI JIANZHANG ; MELLICAN SEAN M</creator><creatorcontrib>TEDROW JASON S ; LINTON CATHIE L ; CHARUKAMNOETKANOK NAHATHAI ; HENRY RODGER ; MEI JIANZHANG ; MELLICAN SEAN M</creatorcontrib><description>A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 , by lattice parameters a, b and c of 7.800 ±0.001 , 13.406 ±0.002 and 13.554 ±0.002 , respectively and α, and γ of 67.155±0.002, 79.724°±0.002° and 84.067±0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.</description><language>eng</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2010</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100629&DB=EPODOC&CC=US&NR=7745622B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20100629&DB=EPODOC&CC=US&NR=7745622B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>TEDROW JASON S</creatorcontrib><creatorcontrib>LINTON CATHIE L</creatorcontrib><creatorcontrib>CHARUKAMNOETKANOK NAHATHAI</creatorcontrib><creatorcontrib>HENRY RODGER</creatorcontrib><creatorcontrib>MEI JIANZHANG</creatorcontrib><creatorcontrib>MELLICAN SEAN M</creatorcontrib><title>Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate</title><description>A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 , by lattice parameters a, b and c of 7.800 ±0.001 , 13.406 ±0.002 and 13.554 ±0.002 , respectively and α, and γ of 67.155±0.002, 79.724°±0.002° and 84.067±0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2010</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNir0KwjAURrs4iPoOHSt4l7S1u0Vx6qJOIiXaWxpIbkJ-hjqIz-Qj-SRWFFyFDw4f54yjW2l757mUgjCuIMne40ppEkH5TiDpI1uk0JxMb4USjSDIoZdz0yENgOp5f0DCoJVBWz24xFvxOQp99yuDRR6fka5I6IJsNXGP02jUculw9uUkijfrfbkFNLpGZ_hlqH192BVFli8ZW7H0j-QFZrhH0A</recordid><startdate>20100629</startdate><enddate>20100629</enddate><creator>TEDROW JASON S</creator><creator>LINTON CATHIE L</creator><creator>CHARUKAMNOETKANOK NAHATHAI</creator><creator>HENRY RODGER</creator><creator>MEI JIANZHANG</creator><creator>MELLICAN SEAN M</creator><scope>EVB</scope></search><sort><creationdate>20100629</creationdate><title>Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate</title><author>TEDROW JASON S ; LINTON CATHIE L ; CHARUKAMNOETKANOK NAHATHAI ; HENRY RODGER ; MEI JIANZHANG ; MELLICAN SEAN M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US7745622B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2010</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>TEDROW JASON S</creatorcontrib><creatorcontrib>LINTON CATHIE L</creatorcontrib><creatorcontrib>CHARUKAMNOETKANOK NAHATHAI</creatorcontrib><creatorcontrib>HENRY RODGER</creatorcontrib><creatorcontrib>MEI JIANZHANG</creatorcontrib><creatorcontrib>MELLICAN SEAN M</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>TEDROW JASON S</au><au>LINTON CATHIE L</au><au>CHARUKAMNOETKANOK NAHATHAI</au><au>HENRY RODGER</au><au>MEI JIANZHANG</au><au>MELLICAN SEAN M</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate</title><date>2010-06-29</date><risdate>2010</risdate><abstract>A crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate characterized in the triclinic crystal system and P-1 space group, when measured with radiation at 0.7107 , by lattice parameters a, b and c of 7.800 ±0.001 , 13.406 ±0.002 and 13.554 ±0.002 , respectively and α, and γ of 67.155±0.002, 79.724°±0.002° and 84.067±0.002, respectively, ways to make it, compositions comprising it, and methods of treatment using it are disclosed.</abstract><oa>free_for_read</oa></addata></record>
fulltext	fulltext_linktorsrc
identifier
ispartof
issn
language	eng
recordid	cdi_epo_espacenet_US7745622B2
source	esp@cenet
subjects	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title	Crystalline N-(4-(4-ammoniumthieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea benzenesulfonate
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T14%3A53%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=TEDROW%20JASON%20S&rft.date=2010-06-29&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS7745622B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true